Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.
Teng-Yu LeeChun Fang TungYen Chun PengHan Chung LienChi Sen ChangPublished in: Journal of digestive diseases (2020)
Patients with intermediate HCC receiving combined TACE and sorafenib had a better TTP, but not OS, than those receiving TACE alone.
Keyphrases